Products/Services Used | Details | Operation |
---|---|---|
Biochemicals> | Page 1. Open Citation: J Med Discov (2017); 2(4):jmd17039; DOI:10.24262/jmd.2.4. 17039 * Correspondence: Shiqiang Lu, PhD, Genscript USA Inc. 860 Centennial Ave. Piscataway, NJ 08854, USA. Email: shiqianglu@genscript … | Get A Quote |
A class of new glycan-reactive broadly neutralizing antibodies represented by PGT121, 10-1074, and PGT128 has recently been discovered that targets specific N-glycans and the peptide region around the V3 domain. However, the glycan specificity and fine epitopes of these bNAbs remain to be further defined. We report here a systematic chemoenzymatic synthesis of homogeneous V3 glycopeptides derived from the HIV-1 JR-FL strain carrying defined N-glycans at N332, N301, and N295 sites. Antibody binding studies revealed that both the nature and site of glycosylation in the context of the V3 domain were critical for high-affinity binding. It was found that antibody PGT128 exhibited specificity for high-manno... More